| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | Clec4g |
| Uniprot No | Q6UXB4 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 55-293aa |
| 氨基酸序列 | KASTERAALLDGHDLLRTNASKQTAALGALKEEVGDCHSCCSGTQAQLQTTRAELGEAQAKLMEQESALRELRERVTQGLAEAGRGREDVRTELFRALEAVRLQNNSCEPCPTSWLSFEGSCYFFSVPKTTWAAAQDHCADASAHLVIVGGLDEQGFLTRNTRGRGYWLGLRAVRHLGKVQGYQWVDGVSLSFSHWNQGEPNDAWGRENCVMMLHTGLWNDAPCDSEKDGWICEKRHNC |
| 预测分子量 | 52.9 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于Clec4g重组蛋白的虚构参考文献示例(仅供格式参考，非真实文献)：
---
1. **标题**: *Clec4g重组蛋白在肝细胞抗病毒反应中的功能研究*
**作者**: Zhang L, et al. (2021)
**摘要**: 本研究通过表达纯化Clec4g重组蛋白，发现其通过识别病毒表面糖蛋白激活NF-κB通路，促进干扰素分泌，揭示了其在肝脏先天免疫中的关键作用。
2. **标题**: *Clec4g重组蛋白的晶体结构及其配体结合机制*
**作者**: Tanaka K, et al. (2019)
**摘要**: 利用X射线晶体学解析Clec4g重组蛋白的C型凝集素结构域，阐明其与β-葡聚糖特异性结合的分子机制，为靶向药物设计提供结构基础。
3. **标题**: *Clec4g重组蛋白调控肝纤维化的实验研究*
**作者**: Wang Y, et al. (2020)
**摘要**: 动物模型实验表明，外源性Clec4g重组蛋白通过抑制TGF-β信号通路减轻肝星状细胞活化，提示其在抗纤维化治疗中的潜在应用。
4. **标题**: *重组Clec4g蛋白作为新型疫苗佐剂的免疫增强效应*
**作者**: Gupta R, et al. (2022)
**摘要**: 研究证明Clec4g重组蛋白可增强抗原提呈细胞对模型抗原的摄取，并促进Th1型免疫应答，为疫苗开发提供了新策略。
---
注：以上内容为模拟生成，实际文献需通过PubMed、Google Scholar等平台检索。
**Background of CLEC4G Recombinant Protein**
CLEC4G (C-type lectin domain family 4 member G), also known as **LSECtin** (Liver and Lymph Node Sinusoidal Endothelial Cell C-type Lectin), is a transmembrane protein belonging to the C-type lectin superfamily. These proteins are characterized by calcium-dependent carbohydrate-binding domains (CRDs) that recognize specific glycan structures on pathogens or host cells. CLEC4G is primarily expressed in liver sinusoidal endothelial cells (LSECs) and lymph node endothelial cells, playing roles in immune surveillance and pathogen recognition.
Structurally, CLEC4G contains a conserved CRD, a stalk region, a transmembrane domain, and a short cytoplasmic tail lacking signaling motifs. It functions as a pattern recognition receptor (PRR), binding to pathogens such as viruses (e.g., hepatitis B and SARS-CoV-2) and bacteria by recognizing glycans like mannose or fucose. This interaction facilitates pathogen uptake and antigen presentation, linking innate and adaptive immunity. Additionally, CLEC4G interacts with immune cells (e.g., T cells) through ligands like lymphotoxin-α, modulating immune responses.
Recombinant CLEC4G protein is produced using expression systems (e.g., mammalian or insect cells) to ensure proper glycosylation and structural integrity. Its applications include studying receptor-ligand interactions, immune modulation mechanisms, and host-pathogen dynamics. In therapeutic research, CLEC4G is explored for targeting liver-specific infections, modulating immune checkpoints in cancer, or developing antiviral strategies. Dysregulation of CLEC4G has been associated with chronic liver diseases, viral persistence, and tumor immune evasion, highlighting its biomedical relevance.
Overall, CLEC4G recombinant protein serves as a vital tool for dissecting its immunoregulatory functions and potential clinical applications in infectious diseases, oncology, and immunotherapy.
×
